Our data reported herein, now provide compelling preclinical rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive lymphomas such as diffuse large B cell lymphoma and also provide justification for testing this promising combination in the preclinical setting in other malignancies. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.